2′,3′-Di-O-acetyl-5′-deoxy-5-fluorocytidine CAS 161599-46-8 Kemurnian ≥99.0% Capecitabine Intermediate Factory
Pasokan Komersial Capecitabine Related Intermediates:
5-Fluorocytosine CAS: 2022-85-7
2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine CAS: 161599-46-8
1,2,3-Tri-O-acetyl-5-deoxy-β-D-ribofuranose CAS: 62211-93-2
Capecitabine CAS: 154361-50-9
jeneng | 2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine |
Nomer CAS | 161599-46-8 |
Nomer CAT | RF-PI176 |
Status Simpenan | Ing Simpenan, Skala Produksi Nganti Ton |
Formula Molekul | C13H16FN3O6 |
Bobot Molekul | 329.28 |
Kondisi Kanggo Nyingkiri | Sensitif Panas |
Merk | Kimia Ruifu |
Item | Spesifikasi |
Penampilan | Bubuk kristal putih utawa kuning |
Impurity Tunggal | ≤0,50% |
Total Impurities | ≤1,0% |
Titik lebur | 178.0~193.0 ℃ |
Mundhut ing Pangatusan | ≤0,50% |
Sisa ing Ignition | ≤0,10% |
Kelembapan (KF) | ≤1,0% |
Assay | ≥99,0% |
Kemurnian / Metode Analisis | ≥99,0% (HPLC) |
Standar Tes | Standar Perusahaan |
Panggunaan | Penengah saka Capecitabine (CAS: 154361-50-9) |
Paket: Botol, tas Aluminium foil, Drum karton, 25kg / Drum, utawa miturut kabutuhan pelanggan.
Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya, kelembapan lan infestasi hama.
Capecitabine (CAS: 154361-50-9) minangka wangun anyar obat pirimidin fluorinated oral.Capecitabine dikembangake dening Roche Pharmaceuticals, lan jeneng komersial yaiku Xeloda.Capecitabine bisa diganti ing vivo dadi 5-FU, obat anti-metabolizim fluorine pyrimidine deoxynucleoside carbamate sing ngarahake sel kanker kanggo nyegah divisi sel lan ngganggu sintesis RNA lan protein.Efek kasebut ana hubungane karo tingkat ekspresi enzim TP ing jaringan neoplastik lan enzim DPD ing ekspresi vivo.Cocog minangka perawatan luwih lanjut kanggo pasien kanker payudara primer utawa metastatik lanjut sing durung nanggapi antibiotik paclitaxel utawa anthracycline.Minangka obat antikanker, umume digunakake kanggo ngobati kanker payudara primer utawa metastatik lanjut, uga kanggo perawatan kanker paru-paru non-sel cilik, kanker pankreas, kanker kandung kemih, kanker rektum, kanker usus besar, kanker lambung, lan tumor padhet liyane. .